This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sfagos, C. Articles by Bourantas, K. L. Search for Related Content PubMed PubMed Citation Articles by Sfagos, C. Articles by Bourantas, K. L. Social Bookmarking                   What's this?

Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients

Neurological Clinic, Eginition Hospital, University of Athens, Athens, Greece

Alexandros C Makis

Pediatric Clinic, University Hospital of Ioannina, Ioannina, Greece, me00350{at}cc.uoi.gr

Aristeidis Chaidos

Hematology Clinic, University Hospital of Ioannina, Ioannina, Greece

Eleftheria C Hatzimichael

Hematology Clinic, University Hospital of Ioannina, Ioannina, Greece

Androniki Dalamaga

Neurological Clinic, Eginition Hospital, University of Athens, Athens, Greece

Katerina Kosma

Neurological Clinic, Eginition Hospital, University of Athens, Athens, Greece

Konstantinos L. Bourantas

Hematology Clinic, University Hospital of Ioannina, Ioannina, Greece

Over the last few years, increased evidence has supported the role of iron dysregulation in the pathogenesis of multiple sclerosis (MS), as iron is essential for myelin formation and oxidative phosphorylation. We studied indices of iron metabolism, such as serum iron, ferritin, transferrin and soluble transferrin receptor (sTFR) levels in 27 MS patients. Seven patients had chronic progressive active disease (CP-A), six had chronic progressive stable (CP-S), ten had relapsing—remitting active (RR-A) and four had relapsing—remitting stable (RR-S) disease. sTFR levels were found to be significantly higher in CP-A (P=0.021) and RR-A (P= 0.004) patients than in controls. sTFR levels were also elevated in CP-S patients but did not reach significance (P=0.064). sTFR values in RR-S patients were comparable to those found in controls (P=0.31). Ferritin levels were significantly elevated only in CP-A patients (P= 0.002). Patients of the CP group had significantly higher ferritin values than the RR patients (P= 0.004). Haemoglobin values as well as iron and transferrin levels were within normal limits in all patients. In conclusion, the increased serum sTFR and ferritin levels in nonanaemic MS patients with active disease reflect the increased iron turnover. The mild elevation of sTFR levels in CP-S patients may indicate active inflammation with ongoing oxidative damage that is not detectable by history or examination.

Key Words: ferritin • iron • multiple sclerosis • transferrin • transferrin receptor

Multiple Sclerosis, Vol. 11, No. 3, 272-275 (2005)
DOI: 10.1191/1352458505ms1171oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Bartels, K. Spate, H. Krampe, and H. Ehrenreich Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 193 - 206. [Abstract] [PDF]

				A Sena, R Pedrosa, V Ferret-Sena, M. Cascais, R Roque, C Araujo, and R Couderc Interferon {beta} therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, July 1, 2008; 14(6): 857 - 859. [Abstract] [PDF]

				N Abo-Krysha and L Rashed The role of iron dysregulation in the pathogenesis of multiple sclerosis: an Egyptian study Multiple Sclerosis, June 1, 2008; 14(5): 602 - 608. [Abstract] [PDF]

				K.M. Mitchell, A.L. Dotson, K.M. Cool, A. Chakrabarty, S.H. Benedict, and S.M. LeVine Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis Multiple Sclerosis, November 1, 2007; 13(9): 1118 - 1126. [Abstract] [PDF]

				H. Ehrenreich, B. Fischer, C. Norra, F. Schellenberger, N. Stender, M. Stiefel, A.-L. Siren, W. Paulus, K.-A. Nave, R. Gold, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis Brain, October 1, 2007; 130(10): 2577 - 2588. [Abstract] [Full Text] [PDF]

				P. Zamboni The Big Idea: Iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis J R Soc Med, November 1, 2006; 99(11): 589 - 593. [Full Text] [PDF]

				C. Exley, G. Mamutse, O. Korchazhkina, E. Pye, S. Strekopytov, A. Polwart, and C. Hawkins Elevated urinary excretion of aluminium and iron in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 533 - 540. [Abstract] [PDF]